Home>
US Stocks>
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals share price today

(AMLX)

Amylyx Pharmaceuticals share price is $4.37 & -₹4.37 as on 12 Dec 2024, 2.30 'hrs' IST

$4.37

▲

-0.14

(-3.1%)

Market is closed - opens 8 PM, 12 Dec 2024

View live Amylyx Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Amylyx Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Amylyx Pharmaceuticals. Get details on the Indian mutual funds that are investing in Amylyx Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Amylyx Pharmaceuticals's financials.

Amylyx Pharmaceuticals share price movements

$4.34
$4.50
$4.37
0.8%
Downside
Day's Volatility :3.67%
Upside
2.89%
$1.58
$19.95
$4.37
63.96%
Downside
52 Weeks Volatility :92.1%
Upside
78.09%

Amylyx Pharmaceuticals Returns

Period	Amylyx Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	75.5%	-8.8%	0.0%
6 Months	160.12%	-2.7%	0.0%
1 Year	-70.31%	6.5%	0.0%
3 Years	-75.82%	5.6%	-20.0%

Amylyx Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$4.51
Open	$4.45
Today's High	$4.5
Today's Low	$4.335
Market Capitalization	$334.5M
Today's Volume	$1.3M
52 Week High	$19.9488
52 Week Low	$1.575
Revenue TTM	$196.5M
EBITDA	$-248.2M
Earnings Per Share (EPS)	$-3.82
Profit Margin	-132.05%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-84.43%

How to invest in Amylyx Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Amylyx Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Amylyx Pharmaceuticals stock in both rupees (INR) and dollars (USD). Search for Amylyx Pharmaceuticals or AMLX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Amylyx Pharmaceuticals or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Amylyx Pharmaceuticals shares which would translate to -0.002 fractional shares of Amylyx Pharmaceuticals as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Amylyx Pharmaceuticals

-63%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for Amylyx Pharmaceuticals on INDmoney from India has reduced in the last 30 days as on Dec 12, 2024. -63% less investors are searching Amylyx Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Amylyx Pharmaceuticals

TCG Crossover Management, LLC
6.77%
Vanguard Group Inc
4.51%
BlackRock Inc
3.89%
Perceptive Advisors LLC
3.10%
Alyeska Investment Group, L.P.
2.95%
683 Capital Management LLC
2.92%

Analyst Recommendation on Amylyx Pharmaceuticals

Buy

53%Buy

46%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Amylyx Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Amylyx Pharmaceuticals

What analysts predicted

Upside of 71.62%

Current:

$4.37

Target:

$7.50

Insights on Amylyx Pharmaceuticals

Price Movement
In the last 7 days, AMLX stock has moved down by -12.1%
Increasing Revenue
Revenue is up for the last 2 quarters, -1.02M → 416.0K (in $), with an average increase of 345.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -72.7M → -72.70M (in $), with an average decrease of 0.0% per quarter
AMLX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 46.2% return, outperforming this stock by 116.5%
Price to Sales
ForAMLX every $1 of sales, investors are willing to pay $1.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $15.4 for every $1 of sales.

Amylyx Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$1.4M	-
Net Income	$-14.8M	-
Net Profit Margin	-1.0K%	-

	FY20	Y/Y Change
Revenue	$650.0K	↓ 54.42%
Net Income	$-44.8M	↑ 202.63%
Net Profit Margin	-6.9K%	↓ 5859.01%

	FY21	Y/Y Change
Revenue	$285.0K	↓ 56.15%
Net Income	$-87.9M	↑ 96.0%
Net Profit Margin	-30.8K%	↓ 23936.74%

	FY22	Y/Y Change
Revenue	$22.2M	↑ 7700.0%
Net Income	$-198.4M	↑ 125.74%
Net Profit Margin	-892.38%	↑ 29942.36%

	FY23	Y/Y Change
Revenue	$380.8M	↑ 1612.94%
Net Income	$49.3M	↓ 124.84%
Net Profit Margin	12.94%	↑ 905.32%

	Q2 FY23	Q/Q Change
Revenue	$98.2M	↑ 37.5%
Net Income	$22.1M	↑ 1303.31%
Net Profit Margin	22.47%	↑ 20.27%

	Q3 FY23	Q/Q Change
Revenue	$102.7M	↑ 4.56%
Net Income	$20.9M	↓ 5.35%
Net Profit Margin	20.35%	↓ 2.12%

	Q4 FY23	Q/Q Change
Revenue	$108.4M	↑ 5.61%
Net Income	$4.7M	↓ 77.36%
Net Profit Margin	4.36%	↓ 15.99%

	Q1 FY24	Q/Q Change
Revenue	$88.6M	↓ 18.26%
Net Income	$-118.8M	↓ 2610.95%
Net Profit Margin	-134.01%	↓ 138.37%

	Q2 FY24	Q/Q Change
Revenue	$-1.0M	↓ 101.15%
Net Income	$-72.7M	↓ 38.8%
Net Profit Margin	7.1K%	↑ 7240.57%

	Q3 FY24	Q/Q Change
Revenue	$416.0K	↓ 140.66%
Net Income	$-72.7M	↑ 0.01%
Net Profit Margin	-17.5K%	↓ 24583.48%

	FY19	Y/Y Change
Total Assets	$3.2M	-
Total Liabilities	$28.6M	-

	FY20	Y/Y Change
Total Assets	$14.1M	↑ 338.01%
Total Liabilities	$80.8M	↑ 182.85%

	FY21	Y/Y Change
Total Assets	$105.6M	↑ 648.82%
Total Liabilities	$256.8M	↑ 217.69%

	FY22	Y/Y Change
Total Assets	$391.5M	↑ 270.64%
Total Liabilities	$50.8M	↓ 80.2%

	FY23	Y/Y Change
Total Assets	$517.5M	↑ 32.19%
Total Liabilities	$84.0M	↑ 65.25%

	Q2 FY23	Q/Q Change
Total Assets	$453.6M	↑ 11.18%
Total Liabilities	$67.2M	↑ 21.54%

	Q3 FY23	Q/Q Change
Total Assets	$466.6M	↑ 2.87%
Total Liabilities	$48.2M	↓ 28.32%

	Q4 FY23	Q/Q Change
Total Assets	$517.5M	↑ 10.9%
Total Liabilities	$84.0M	↑ 74.38%

	Q1 FY24	Q/Q Change
Total Assets	$417.5M	↓ 19.32%
Total Liabilities	$93.0M	↑ 10.71%

	Q2 FY24	Q/Q Change
Total Assets	$332.2M	↓ 20.43%
Total Liabilities	$70.9M	↓ 23.83%

	Q3 FY24	Q/Q Change
Total Assets	$250.7M	↓ 24.52%
Total Liabilities	$54.5M	↓ 23.07%

	FY19	Y/Y Change
Operating Cash Flow	$-10.7M	-
Investing Cash Flow	$-151.0K	-
Financing Cash Flow	$668.0K	-

	FY20	Y/Y Change
Operating Cash Flow	$-36.7M	↑ 243.38%
Investing Cash Flow	$-151.0K	↑ 0.0%
Financing Cash Flow	$46.8M	↑ 6909.43%

	FY21	Y/Y Change
Operating Cash Flow	$-74.8M	↑ 103.83%
Investing Cash Flow	$-46.4M	↑ 30632.45%
Financing Cash Flow	$158.5M	↑ 238.52%

	FY22	Y/Y Change
Operating Cash Flow	$-179.9M	↑ 140.47%
Investing Cash Flow	$-239.0M	↑ 414.99%
Financing Cash Flow	$431.8M	↑ 172.41%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$8.6M	↓ 269.74%
Investing Cash Flow	$123.2M	↑ 120.06%
Financing Cash Flow	$1.4M	↑ 33.08%

Amylyx Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Amylyx Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Amylyx Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amylyx Pharmaceuticals, Inc.	-29.97%	160.12%	-70.31%	-75.82%	-75.82%
Regeneron Pharmaceuticals, Inc.	-5.85%	-24.7%	-11.77%	17.09%	105.58%
Biontech Se	12.25%	24.31%	22.8%	-57.11%	240.97%
Alnylam Pharmaceuticals, Inc.	-5.5%	58.79%	40.79%	36.33%	111.58%
Vertex Pharmaceuticals Incorporated	-4.43%	-2.24%	15.61%	124.98%	113.34%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amylyx Pharmaceuticals, Inc.	2.51	NA	NA	-4.37	-0.84	-0.43	NA	2.86
Regeneron Pharmaceuticals, Inc.	19.27	19.27	1.17	45.03	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.24	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amylyx Pharmaceuticals, Inc.	Buy	$334.5M	-75.82%	2.51	-132.05%
Regeneron Pharmaceuticals, Inc.	Buy	$86.6B	105.58%	19.27	33.61%
Biontech Se	Buy	$28.0B	240.97%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$33.0B	111.58%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$122.1B	113.34%	32.84	-4.51%

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.

Organization	Amylyx Pharmaceuticals
Employees	384
CEO	Mr. Joshua B. Cohen
Industry	Services

Management People of Amylyx Pharmaceuticals

Name	Title
Mr. Joshua B. Cohen	Co-Founder, Co-CEO & Director
Mr. Justin B. Klee	Co-Founder, Co-CEO & Director
Mr. James M. Frates M.B.A.	Chief Financial Officer
Ms. Gina M. Mazzariello J.D.	Chief Legal Officer & General Counsel
Dr. Camille L. Bedrosian M.D.	Chief Medical Officer
Mr. Tom Holmes	Chief Technical Operations Officer
Ms. Lindsey Allen	Head of Investor Relations & Communications
Ms. Shauna Horvath	Head of Global Marketing
Ms. Linda A. Arsenault	Chief Human Resources Officer
Mr. Chris Aiello	Head of Canada & GM

Important FAQs about investing in Amylyx Pharmaceuticals from India :

What is Amylyx Pharmaceuticals share price today?

Amylyx Pharmaceuticals (AMLX) share price today is $4.37.

Can Indians buy Amylyx Pharmaceuticals shares?

Yes, Indians can invest in the Amylyx Pharmaceuticals (AMLX) from India.

With INDmoney, you can buy Amylyx Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amylyx Pharmaceuticals at zero transaction cost.

How can I buy Amylyx Pharmaceuticals shares from India?

It is very easy to buy Amylyx Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amylyx Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Amylyx Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Amylyx Pharmaceuticals stocks?

To start investing in Amylyx Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.